LobbyingModel Medicines lobbying by quarter
Model Medicines's latest lobbying report covers Q1 2025, at under $5,000. Its first report covers Q4 2023; the issues it reports most are Medical/Disease Research/Clinical Labs and Pharmacy.
Model Medicines
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2023
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Medical research and clinical labs$0 · 5 reports
- Pharmacy$0 · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Health & Human Services, Dept of (HHS)4 reports
- SENATE3 reports
- HOUSE OF REPRESENTATIVES1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Resolute-Dc | $0 | 6 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ADAM WILCZEWSKI | Chief of Staff, International Trade Administration | Q4 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 25/07/09for Q1 2025 | Resolute-Dc | Under $5,000 |
| 25/04/21for Q1 2025 | Resolute-Dc | Under $5,000 |
| 25/01/15for Q4 2024 | Resolute-Dc | Under $5,000 |
| 24/10/14for Q3 2024 | Resolute-Dc | Under $5,000 |
| 24/07/19for Q2 2024 | Resolute-Dc | Under $5,000 |
| 24/04/22for Q1 2024 | Resolute-Dc | Under $5,000 |
| 24/01/19for Q4 2023 | Resolute-Dc | Under $5,000 |
| 23/12/31for Q4 2023 | Resolute-Dc | Under $5,000 |
| 23/12/31for Q4 2023 | Resolute-Dc | Under $5,000 |
| 23/11/10for Q4 2023 | Resolute-Dc | Under $5,000 |